Divi's Laboratories Stock

Divi's Laboratories Equity

The The Equity of Divi's Laboratories (DIVISLAB.NS) as of Aug 11, 2026 is 149.69 B INR. In the previous year, The Equity was 135.71 B INR — a change of 10.30% (higher).

Equity

149.69 BINR

YoY

10.30%

Last updated:

In 2026, Divi's Laboratories's equity was 149.69 B INR, a 10.30% increase from the 135.71 B INR equity in the previous year.

Access this data via the Eulerpool API

Divi's Laboratories Stock analysis

What does Divi's Laboratories do? Divi's Laboratories Ltd. is a pharmaceutical company based in Hyderabad, India. It was founded in 1990 and has become one of the leading manufacturers of active ingredients and formulations for the pharmaceutical industry in recent years. The company was founded by Dr. Murali Divi, who built the company on principles of quality, technology, and innovation. Divi's Laboratories now employs approximately 13,000 employees and operates production facilities in India and the USA. The company operates in various sectors, including generics, custom synthesis, research and development, and nutraceuticals. Its products are used worldwide and are approved in over 95 countries. Divi's Laboratories follows a vertically integrated supply chain model, producing high-quality active ingredients and developing its own formulations for the pharmaceutical industry. The company always relies on innovative technologies and continuous improvement of product quality. Its product range includes a wide range of active ingredients for various therapeutic areas, such as antibiotics, antidepressants, antihypertensives, antidiabetics, static lipid-lowering agents, and antipsychotics. Divi's Laboratories has state-of-the-art production facilities, strict quality controls, and advanced analytical facilities for all pharmaceutical ingredients. In addition to its active ingredients, the company is also known for its custom synthesis services, which involve the production of customer-specific active ingredients for the pharmaceutical industry. Divi's Laboratories offers a tailored service that meets the specific requirements of customers, ranging from the development of new active ingredients and formulations to the production of small or medium quantities of active ingredients. In the area of research and development, Divi's Laboratories works closely with academic institutions and other pharmaceutical companies to leverage the latest scientific knowledge and develop innovative products. The company invests a significant sum in research and development annually. In addition to active ingredients and custom synthesis services, Divi's Laboratories also offers a range of nutraceuticals. These products, such as vitamins, minerals, and other dietary supplements, are used to support a healthy lifestyle. In summary, Divi's Laboratories is an India-based pharmaceutical company specializing in the manufacture of active ingredients and formulations for the pharmaceutical industry. The company operates to the highest quality standards and relies on innovative technologies and sustainable product development. The wide product range and custom synthesis services offer customers a tailored solution for their needs. Divi's Laboratories is a leading provider of active ingredients and has made a name for itself in the pharmaceutical and nutraceutical industry due to its high quality and productivity. Divi's Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Divi's Laboratories's Equity

Divi's Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Divi's Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Divi's Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Divi's Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Divi's Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Divi's Laboratories stock

The Equity of Divi's Laboratories is 149.69 B INR in 2026.

The Equity of Divi's Laboratories changed from 135.71 B INR to 149.69 B INR, representing a 10.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Divi's Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Divi's Laboratories historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Divi's Laboratories

All Key Metrics — Divi's Laboratories